Comparative Pharmacology
Head-to-head clinical analysis: ORETICYL 50 versus PRINZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORETICYL 50 versus PRINZIDE.
ORETICYL 50 vs PRINZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and increasing diuresis.
PRINZIDE is a combination of lisinopril (an ACE inhibitor) and hydrochlorothiazide (a thiazide diuretic). Lisinopril inhibits angiotensin-converting enzyme, reducing angiotensin II formation, leading to vasodilation and decreased aldosterone secretion. Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting diuresis and reducing plasma volume.
Hydrochlorothiazide 50 mg orally once daily in the morning; may increase to 100 mg daily in divided doses.
Oral, 1-2 tablets daily; each tablet contains 25 mg hydrochlorothiazide and 5 mg lisinopril. Adjust based on blood pressure response; maximum daily dose: 2 tablets.
None Documented
None Documented
Terminal elimination half-life: 6–15 hours (mean 10 hours), prolonged in renal impairment (up to 24–30 hours) and elderly.
Lisinopril: terminal half-life 12 hours (effective half-life 30 hours due to prolonged ACE binding). Hydrochlorothiazide: terminal half-life 6-15 hours (biphasic, initial phase 2-4 h, terminal phase 6-15 h) with prolonged terminal phase in renal impairment.
Renal: ~95% (50% as unchanged drug, remainder as inactive metabolites); Biliary/fecal: <5%.
Lisinopril is excreted unchanged in urine (100% renal elimination); hydrochlorothiazide is excreted 95% renally as unchanged drug and 5% via bile.
Category C
Category C
Diuretic Combination
ACE Inhibitor / Diuretic Combination